Skip navigation

The following active life science portfolio companies and select exits are, or were, managed by members of the Lightstone team in the healthcare portfolios of Morgenthaler and/or ATV as indicated.

Alexo Therapeutics
>

Alexo Therapeutics

Alexo Therapeutics is a biopharmaceutical company developing novel biologics to help the immune system eradicate cancer.

Lightstone Lead: Jason Lettmann
Fund: Lightstone Ventures I
Location: Dublin, Ireland
Asterand Bioscience
>

Asterand Bioscience

Asterand Bioscience provides tissue and tissue-based research solutions for pharmaceutical, biotechnology, and diagnostic R&D.

Lightstone Lead: Chris Christoffersen, Ph.D.
Fund: Morgenthaler
Location: Cambridge, MA
Cala Health
>

Cala Health

Cala Health is a medical device company developing novel therapies based on recent neuroscience discoveries from Stanford University.

Lightstone Lead: Mike Carusi
Fund: Lightstone Ventures I
Location: Burlingame, CA
Carrick Therapeutics
>

Carrick Therapeutics

Carrick Therapeutics is building an innovative portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer.

Lightstone Lead: Jason Lettmann
Fund: Lightstone Ventures I
Location: Dublin, Ireland
Cerevance
>

Cerevance

Cerevance is a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric disorders

Lightstone Lead: Jason Lettmann
Fund: Lightstone Ventures I
Location: Boston, MA
Claret Medical
>

Claret Medical

Claret Medical is a developer of innovative solutions for cerebral protection during structural heart, vascular and cardiac surgery procedures.

Lightstone Lead: Hank Plain
Fund: Lightstone Ventures I
Location: Santa Rosa, CA
EarLens
>

EarLens

EarLens is developing next generation hearing technology that uses light to transmit sound and energy directly to the eardrum enabling users to appreciate high frequency sounds and improved speech recognition, especially in noisy environments.

Lightstone Lead: Hank Plain
Fund: Lightstone Ventures I
Location: Redwood City, CA
Elcelyx
>

Elcelyx

Elcelyx is a biopharmaceutical company developing a wide range of products based on the science of nutrient sensing. The therapies are directed at the treatment of diabetes and obesity.

Fund: Morgenthaler
Location: San Diego, CA
EndoGastric Solutions
>

EndoGastric Solutions

Endogastric Solutions is developing an endoscopic medical device that can restore the competency of the anti-reflux barrier, which is distorted in GERD patients and contributes to acid reflux.

Lightstone Lead: Mike Carusi
Legacy Fund: ATV
Location: Redwood City, CA / Redmond, WA
FIRE1
>

FIRE1

FIRE1 is a medical device company developing novel remote monitoring devices to improve patient quality of life and outcomes while lowering overall healthcare costs.

Lightstone Lead: Jason Lettmann
Fund: Lightstone Ventures I
Location: Dublin, Ireland
ForSight Labs
>

ForSight Labs

Lightstone Lead:
Fund:
Location:
ForSight VISION5
>

ForSight VISION5

VISION5 is a medical device company focused on a novel anterior segment drug delivery program for ophthalmic drugs.  The company was incubated within ForSight Labs.

Lightstone Lead: Robin Bellas
Legacy Fund: Morgenthaler
Location: Menlo Park, CA
Holaira
>

Holaira

Holaira is a medical device company developing novel devices for treating obstructive lung diseases. The company was incubated within The Foundry.

Lightstone Lead:
Legacy Fund: ATV & Morgenthaler
Location: Minneapolis, MN
Hydra Biosciences
>

Hydra Biosciences

Hydra Biosciences is a biopharmaceutical company developing novel drugs to treat pain, inflammation, anxiety and other diseases using its expertise in novel ion channels.

Lightstone Lead: Jean George
Legacy Fund: ATV
Location: Cambridge, MA
Mosaic Biosciences
>

Mosaic Biosciences

Mosaic Biosciences is developing synthetic materials for native tissue regeneration. Applications include wound healing, bone regeneration, cartilage repair, stem cell therapy, and dermal fillers.

Lightstone Lead:
Legacy Fund: Morgenthaler
Location: Boulder, CO
Moximed
>

Moximed

Moximed is a medical device company that is developing innovative devices for patients with osteoarthritis of the knee.  The company was incubated within the ExploraMed incubator.

Lightstone Lead: Hank Plain
Legacy Fund: Morgenthaler
Location: Hayward, CA
Nimbus Therapeutics
>

Nimbus Therapeutics

Nimbus Therapeutics is a biotechnology company that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was formed using an LLC model. Its lead program was acquired by Gilead Sciences in 2016.

 

Lead program acquired by Gilead Sciences (NASDAQ: GILD)

Lightstone Lead: Chris Christoffersen, Ph.D.
Fund: Lightstone Ventures I
Location: Cambridge, MA
Powervision
>

Powervision

PowerVision is developing a proprietary fluid-controlled accommodating intraocular lens (IOL) technology to restore the vision of youth to millions of middle-aged or elderly individuals.

Lightstone Lead: Mike Carusi
Legacy Fund: ATV
Location: Belmont, CA
Principia
>

Principia

Principia is a biopharmaceutical company developing novel compounds with enhanced sensitivity, high potency, and longer duration of effect.

Lightstone Lead:
Legacy Fund: Morgenthaler
Location: Menlo Park, CA
Promedior
>

Promedior

Promedior Pharmaceuticals is a biopharmaceutical company developing a proprietary platform of pentraxin therapeutics for the treatment of fibrosis.

Lightstone Lead: Jason Lettmann
Fund: Morgenthaler
Location: Lexington, MA
Relievant Medsystems
>

Relievant Medsystems

Relievant is a medical device company developing a new, minimally invasive technology that targets the source of chronic low back pain with a simple one-hour treatment.

Lightstone Lead: Jason Lettmann
Legacy Fund: Morgenthaler
Location: Redwood City, CA
Second Genome
>

Second Genome

Second Genome is a biopharmaceutical company targeting the human microbiome to discover novel therapies for infection, inflammation, and metabolic diseases.

Lightstone Lead:
Fund: ATV & Morgenthaler
Location: San Bruno, CA
SetPoint Medical
>

SetPoint Medical

SetPoint Medical is a medical device company developing a neuromodulation platform for the treatment of debilitating inflammatory diseases, such as Crohn's Disease and Rheumatoid Arthritis. 

Lightstone Lead: Hank Plain
Fund: Morgenthaler
Location: Valencia, CA
Spine Wave
>

Spine Wave

Spine Wave is developing and marketing novel devices for spine surgery, specifically spinal fusion, vertebral compression fracture repair, and nucleus replacement and augmentation.

Lightstone Lead:
Legacy Fund: Morgenthaler
Location: Shelton, CT
Thrasos Therapeutics
>

Thrasos Therapeutics

Thrasos is a biotherapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of kidney disease.

Lightstone Lead: Jean George
Legacy Fund: ATV
Location: Montreal, QC
Tizona Therapeutics
>

Tizona Therapeutics

Tizona Therapeutics is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases.

Lightstone Lead: Jean George
Fund: Lightstone Ventures I
Location: South San Francisco, CA
Tragara
>

Tragara

Tragara Pharmaceuticals is a biopharmaceutical company developing proprietary drugs for the treatment of various cancers.

Lightstone Lead: Chris Christoffersen, Ph.D.
Legacy Fund: Morgenthaler
Location: San Diego, CA
Vapotherm
>

Vapotherm

Vapotherm is a commercial-stage company developing high flow therapy for clinically effective respiratory support.

Lightstone Lead: Jason Lettmann
Fund: Morgenthaler
Location: Exeter, NH
Willow
>

Willow

Willow is developing a wearable breast pump that allows women to achieve their breastfeeding goals without pressing pause on their own lives. The company, formerly known as NC7, was incubated within ExploraMed.

Lightstone Lead: Mike Carusi
Fund: Lightstone Ventures I
Location: Mountain View, CA
Acceleron
>

Acceleron

Acceleron Pharma is a biopharmaceutical company focused on the development and commercialization of novel protein therapeutics for orphan diseases and cancer based on the TGF-β protein superfamily. The company had an IPO in 2013.

 

NASDAQ: XLRN

Lightstone Lead: Jean George
Fund: ATV
Location: Cambridge, MA
Altura Medical
>

Altura Medical

Altura is a medical device company focused on developing innovative devices and methods for the percutaneous treatment of abdominal aortic aneurysms (AAA). The company was acquired by Lombard Medical in 2015.

 

Acquired by Lombard Medical (NASDAQ: EVAR)

Lightstone Lead: Mike Carusi
Fund: ATV
Location: San Clemente, CA
Ardian
>

Ardian

Ardian is a medical device company that developed a first-in-class renal denervation catheter for the treatment of hypertension. The company was incubated within The Foundry and was acquired by Medtronic in 2011. 

Acquired by Medtronic (NYSE: MDT)

Lightstone Lead:
Fund: ATV & Morgenthaler
Location: Mountain View, CA
Avidia
>

Avidia

Avidia is a biopharmaceutical company focused on discovering and developing a new class of human therapeutic proteins called avimers™. The company was acquired by Amgen in 2006.

Aquired by Amgen (NASDAQ: AMGN)

Lightstone Lead: Chris Christoffersen, Ph.D.
Legacy Fund: Morgenthaler
Location: Mountain View, CA
Cabochon
>

Cabochon

Cabochon Aesthetics is a medical device company developing effective, scientific solutions for the aesthetic treatment of cellulite. The company was incubated within The Foundry and was acquired by Ulthera in 2014.

 

Acquired by Ulthera, Inc.

Lightstone Lead: Hank Plain
Fund: Morgenthaler
Location: Menlo Park, CA
Calithera
>

Calithera

Calithera Biosciences is a biopharmaceutical company developing novel therapeutics for the treatment of cancer and other proliferative diseases by targeting the dysregulated metabolic pathways of cancer cells. The company had an IPO in 2014.

 

NASDAQ: CALA

Fund: ATV & Morgenthaler
Location: South San Francisco, CA
Catabasis
>

Catabasis

Catabasis is leveraging the therapeutic potential of omega-3 fatty acids and other clinically validated compounds to create new medicines for the treatment of inflammatory and metabolic diseases. The company had an IPO in 2015.

 

NASDAQ: CATB

Lightstone Lead: Jean George
Fund: LSV & ATV
Location: Cambridge, MA
Catalyst Biosciences
>

Catalyst Biosciences

Catalyst Biosciences is developing therapeutics that utilize protease enzymes as biopharmaceuticals. Catalyst calls these redirected engineered proteases "Alterase™ Therapeutics." The company completed a reverse merger with Targacept in 2015.

 

NASDAQ: CBIO

Lightstone Lead: Chris Christoffersen, Ph.D.
Fund: Morgenthaler
Location: South San Francisco, CA
FivePrime
>

FivePrime

FivePrime Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of a complete range of innovative protein and antibody drugs. The company had an IPO in 2013.

 

NASDAQ: FPRX

Lightstone Lead: Jean George
Fund: ATV
Location: South San Francisco, CA
Flex Pharma
>

Flex Pharma

Flex Pharma is a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders, and has demonstrated initial human efficacy related to muscle cramping. The company had an IPO in 2015.

 

NASDAQ: FLKS

Lightstone Lead: Jean George
Fund: Lightstone Ventures I
Location: Boston, MA
FoldRx
>

FoldRx

FoldRx Pharmaceuticals, Inc. is a biopharmaceutical company developing disease modifying drug therapies for diseases of protein misfolding and amyloidosis.

Acquired by Pfizer (NYSE: PFE)

Lightstone Lead: Chris Christoffersen, Ph.D.
Legacy Fund: Morgenthaler
Location: Cambridge, MA
ForSight VISION2
>

ForSight VISION2

VISION2 developed a proprietary ocular punctal plug drug delivery system. It is non-invasive and capable of delivering a variety of drugs to the eye through controlled release to the tear film. 

Acquired by QLT, Inc. (NASDAQ: QLTI)

Lightstone Lead: Robin Bellas
Legacy Fund: Morgenthaler
Location: Menlo Park, CA
ForSight VISION4
>

ForSight VISION4

VISION4 is a medical device company focused on developing novel drug delivery therapies for treatment of retinal diseases.  The company was incubated within ForSight Labs.

Lightstone Lead: Robin Bellas
Fund: Morgenthaler
Location: Menlo Park, CA
GI Dynamics
>

GI Dynamics

GI Dynamics is a medical device company developing a device to treat metabolic disease with gastric bypass.  The company had an IPO on the Australian Securities Exchange in 2011.

 ASX: GID

Lightstone Lead: Mike Carusi
Fund: ATV
Location: Lexington, MA
Hypnion
>

Hypnion

Hypnion is a biopharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders such as sleep, wake-alertness disorders, circadian rhythm abnormalities.

Acquired by Eli Lilly (NYSE: LLY)

Lightstone Lead: Jean George
Legacy Fund: ATV
Location: Lexington, MA
IPC
>

IPC

IPC is a leading national physician group practice focused on the delivery of hospital medicine.

NASDAQ: IPCM

Lightstone Lead: Robin Bellas
Legacy Fund: Morgenthaler
Location: North Hollywood, CA
IVS
>

IVS

IVS is a medical device company developing a femoral artery closure device using a memory-metal clip to achieve hemostasis at the access site after a catheterization procedure.

Acquired by Abbott (NYSE: ABT)

Lightstone Lead: Robin Bellas
Legacy Fund: Morgenthaler
Location: Sunnyvale, CA
MicroVention
>

MicroVention

MicroVention develops and markets innovative neuroendovascular technologies for the treatment of vascular diseases in small vessels.  The company was acquired by Terumo in 2006.

Acquired by Terumo (Tokyo Stock Exchange)

Lightstone Lead: Mike Carusi
Legacy Fund: ATV
Location: Tustin, CA
Miramar Labs
>

Miramar Labs

Miramar Labs is developing and marketing a non-invasive, lasting treatment for hyperhydrosis and excessive sweating using microwave energy.  The company was incubated within The Foundry.

 

OTCQB: MRLB

Lightstone Lead: Hank Plain
Fund: Morgenthaler
Location: Sunnyvale, CA
Morphotek
>

Morphotek

Morphotek is a biopharmaceutical company developing novel classes of biological-based products to treat cancer, inflammation and infectious diseases. The company was acquired by Eisai Inc. in 2007.

 

Acquired by Eisai (TYO: 4523)

 

Lightstone Lead: Chris Christoffersen, Ph.D.
Fund: Morgenthaler
Location: Exton, PA
Nimbus Therapeutics
>

Nimbus Therapeutics

Nimbus Therapeutics is a biotechnology company that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was formed using an LLC model. Its lead program was acquired by Gilead Sciences in 2016.

 

Lead program acquired by Gilead Sciences (NASDAQ: GILD)

Lightstone Lead: Chris Christoffersen, Ph.D.
Fund: Lightstone Ventures I
Location: Cambridge, MA
OncoMed
>

OncoMed

OncoMed is developing monoclonal antibodies that target tumor initiating cells, also known as "cancer stem cells." The company had an IPO in 2013.

 

NASDAQ:OMED

Lightstone Lead:
Fund: Morgenthaler
Location: Redwood City, CA
Orexigen
>

Orexigen

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for the treatment of obesity. The company had an IPO in 2007.

NASDAQ: OREX

Lightstone Lead: Chris Christoffersen, Ph.D.
Legacy Fund: Morgenthaler
Location: La Jolla, CA
Plexxikon
>

Plexxikon

Plexxikon is developing novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to develop a portfolio of competitively differentiated therapeutic programs. The company was acquired by Daiichi Sankyo in 2011.

Acquired by Daiichi Sankyo (TYO: 4568)

Lightstone Lead: Mike Carusi
Fund: ATV
Location: Berkeley, CA
Portola
>

Portola

Portola is developing innovative therapeutics for cardiovascular and autoimmune/inflammatory diseases. The company had an IPO in 2013.

 

NASDAQ: PTLA

 

Lightstone Lead: Jean George
Fund: ATV
Location: South San Francisco, CA
Proteolix
>

Proteolix

Proteolix is a biopharmaceutical company developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.

Acquired by Onyx (NASDAQ: ONXX)

Lightstone Lead: Jean George
Legacy Fund: ATV
Location: South San Francisco, CA
Ra Pharma
>

Ra Pharma

Ra Pharmaceuticals is developing a new class of drugs with the specificity of antibodies and the oral bioavailability of small molecules.  The company had an IPO in 2016.

 

NASDAQ:RARX

Lightstone Lead: Jason Lettmann
Fund: Morgenthaler & Lightstone Ventures I
Location: Cambridge, MA
Scioderm
>

Scioderm

Scioderm is focused on the development of innovative drugs for the treatment of chronic diseases of the skin. The company was acquired by Amicus Therapeutics in 2015.

 

Acquired by Amicus Therapeutics (NASDAQ: FOLD)

Lightstone Lead: Chris Christoffersen, Ph.D.
Fund: Morgenthaler
Location: Durham, NC.
Threshold
>

Threshold

Threshold Pharmaceuticals is developing therapeutics based on tumor hypoxia, a platform that offers potential to treat most solid tumors. The company had an IPO in 2005.

NASDAQ: THLD

Lightstone Lead: Chris Christoffersen, Ph.D.
Legacy Fund: Morgenthaler
Location: South San Francisco, CA
Transcend Medical
>

Transcend Medical

Transcend Medical is a medical device company focused on the development of devices for the treatment of glaucoma, the leading cause of adult irreversible blindness.  The company was acquired by Alcon (Novartis) in 2016.

 

Acquired by Alcon (NYSE: NVS)

Lightstone Lead: Robin Bellas
Fund: Morgenthaler
Location: Menlo Park, CA
Twelve
>

Twelve

Twelve is a medical device company developing a novel device for the treatment of chronic cardiovascular disease.  The company was incubated within The Foundry and was acquired by Medtronic in 2015.

 

Acquired by Medtronic (NYSE: MDT)

Lightstone Lead: Hank Plain
Fund: Morgenthaler
Location: Menlo Park, CA
Verastem
>

Verastem

Verastem is bringing breakthroughs in cancer stem cell research into new medicines for the treatment of major cancers, such as breast cancer. The company had an IPO in 2012.

NASDAQ: VSTM

Lightstone Lead: Jean George
Legacy Fund: ATV
Location: Cambridge, MA
ZELTIQ
>

ZELTIQ

ZELTIQ is developing and marketing a non-invasive, office-based procedure that uses Cryolipolysis, a proprietary cooling technology, to eliminate fat. ZELTIQ had an IPO in 2011.

NASDAQ: ZLTQ

Lightstone Lead: Jean George
Legacy Fund: ATV
Location: Pleasanton, CA
';